Cyrille J Cohen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2691321/publications.pdf

Version: 2024-02-01

44	4,606	218677	265206
papers	citations	26 h-index	42 g-index

44	44	44	7037
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. Experientia Supplementum (2012), 2022, 113, 253-294.	0.9	1
2	Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma. Haematologica, 2022, 107, 2395-2407.	3.5	7
3	A novel role for an old target: CD45 for breast cancer immunotherapy. OncoImmunology, 2021, 10, 1929725.	4.6	12
4	Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide. Frontiers in Medicine, 2021, 8, 675963.	2.6	6
5	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. Journal of Clinical Investigation, 2021, 131, .	8.2	15
6	Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet, The, 2021, 398, 2093-2100.	13.7	748
7	Noninvasive Tracking of Natural Killer Cells Using Gold Nanoparticles. ACS Omega, 2021, 6, 28507-28514.	3.5	5
8	Targeting glycosylated antigens on cancer cells using siglecâ€7/9â€based CAR Tâ€cells. Molecular Carcinogenesis, 2020, 59, 713-723.	2.7	36
9	TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature, 2019, 571, 265-269.	27.8	581
10	A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function. , 2019, 7, 243.		51
11	Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides. , 2019, 7, 135.		18
12	T-cells â€œÃ la CAR-T(e)â€•â€“ Genetically engineering T-cell response against cancer. Advanced Drug Delivery Reviews, 2019, 141, 23-40.	13.7	17
13	Increased RNA Editing May Provide a Source for Autoantigens in Systemic Lupus Erythematosus. Cell Reports, 2018, 23, 50-57.	6.4	91
14	The mutational status of p53 can influence its recognition by human T-cells. OncoImmunology, 2017, 6, e1285990.	4.6	17
15	Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy. ACS Nano, 2017, 11, 11127-11134.	14.6	101
16	Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor. Frontiers in Immunology, 2017, 8, 1212.	4.8	20
17	MHC-multimer guided isolation of neoepitopes specific T cells as a potent-personalized cancer treatment strategy. OncoImmunology, 2016, 5, e1159370.	4.6	3
18	Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL. Journal of Immunotherapy, 2016, 39, 321-328.	2.4	10

#	Article	IF	Citations
19	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunology Research, 2016, 4, 669-678.	3.4	117
20	Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. Molecular Therapy, 2016, 24, 1078-1089.	8.2	51
21	In-vitro Optimization of Nanoparticle-Cell Labeling Protocols for In-vivo Cell Tracking Applications. Scientific Reports, 2015, 5, 15400.	3.3	65
22	TLR4 Expression Is Associated with Left Ventricular Dysfunction in Patients Undergoing Coronary Artery Bypass Surgery. PLoS ONE, 2015, 10, e0120175.	2.5	27
23	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. Journal of Clinical Investigation, 2015, 125, 3981-3991.	8.2	328
24	Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific T-Cells in Vivo with Gold Nanoparticles and CT Imaging. ACS Nano, 2015, 9, 6363-6372.	14.6	201
25	Engineering T-Cell Specificity Genetically to Generate Anti-melanoma Reactivity. Methods in Molecular Biology, 2015, , 1.	0.9	3
26	An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget, 2014, 5, 10949-10958.	1.8	25
27	Out of the bitter came forth sweet. OncoImmunology, 2014, 3, e27399.	4.6	15
28	Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity. Journal of Immunology, 2013, 191, 4121-4129.	0.8	87
29	Enhanced antitumor activity mediated by human 4â€1BBâ€engineered T cells. International Journal of Cancer, 2013, 133, 2903-2913.	5.1	22
30	How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer. Frontiers in Immunology, 2012, 3, 186.	4.8	13
31	Incorporation of Transmembrane Hydrophobic Mutations in the TCR Enhance Its Surface Expression and T Cell Functional Avidity. Journal of Immunology, 2012, 188, 5538-5546.	0.8	57
32	CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunology, Immunotherapy, 2012, 61, 1833-1847.	4.2	43
33	Genetically modulating T-cell function to target cancer. Seminars in Cancer Biology, 2012, 22, 14-22.	9.6	36
34	Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunology, Immunotherapy, 2010, 59, 1551-1560.	4.2	35
35	Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition. Journal of Immunology, 2010, 184, 6232-6241.	0.8	69
36	Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes. Human Gene Therapy, 2009, 20, 630-640.	2.7	70

#	Article	IF	Citations
37	Relationship of p53 Overexpression on Cancers and Recognition by Anti-p53 T Cell Receptor-Transduced T Cells. Human Gene Therapy, 2008, 19, 1219-1231.	2.7	38
38	Extrathymic Generation of Tumor-Specific T Cells from Genetically Engineered Human Hematopoietic Stem Cells via Notch Signaling. Cancer Research, 2007, 67, 2425-2429.	0.9	87
39	Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide Bond. Cancer Research, 2007, 67, 3898-3903.	0.9	315
40	Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood, 2007, 109, 5168-5177.	1.4	101
41	Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes. Journal of Immunology, 2006, 177, 6548-6559.	0.8	287
42	Enhanced Antitumor Activity of Murine-Human Hybrid T-Cell Receptor (TCR) in Human Lymphocytes Is Associated with Improved Pairing and TCR/CD3 Stability. Cancer Research, 2006, 66, 8878-8886.	0.9	394
43	High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation. Molecular Therapy, 2006, 13, 151-159.	8.2	260
44	Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR. Journal of Immunology, 2005, 175, 5799-5808.	0.8	121